The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Atrial Flutter

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Atrial Flutter


High impact information on Atrial Flutter

  • Enhanced atrioventricular conduction during atrial flutter after intravenous adenosine [6].
  • Amiodarone had fewer effects on atrial refractory period and conduction velocity than did ibutilide and propafenone, and it terminated atrial flutter in only 4 (33%) of 12 patients [7].
  • CONCLUSIONS: Ibutilide, with a unique increase in atrial refractoriness, was more effective in conversion of atrial flutter than were propafenone and amiodarone [7].
  • Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy [8].
  • BACKGROUND: Previous electrophysiological studies in patients with typical atrial flutter suggested that the slow conduction zone might be located in the low right atrial isthmus, which is a path formed by orifice of inferior vena cava, eustachian valve/ridge, coronary sinus ostium, and tricuspid annulus [9].

Chemical compound and disease context of Atrial Flutter

  • Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators [10].
  • Propafenone predominantly decreased conduction velocity with use dependency and significantly increased atrial refractory period, but it only converted atrial flutter in 4 (33%) of 12 patients [7].
  • Quinidine increased effective refractory period (+40%; p less than .01), functional refractory period (+27%; p less than .01), conduction time at sinus cycle length (+13%; p less than .01), conduction time at an atrial paced cycle length of 150 msec (+18%; p less than .01), and atrial flutter cycle length (+31%; p less than .01) [11].
  • Diltiazem, a calcium channel blocker, has been shown to be safe and effective in the treatment of patients in atrial fibrillation and/or atrial flutter [12].
  • We studied the effects of procainamide and N-acetylprocainamide (NAPA) in a conscious dog preparation of atrial flutter resulting from circus movement around the tricuspid orifice [13].

Biological context of Atrial Flutter


Anatomical context of Atrial Flutter


Gene context of Atrial Flutter


Analytical, diagnostic and therapeutic context of Atrial Flutter


  1. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Antman, E.M., Stone, P.H., Muller, J.E., Braunwald, E. Ann. Intern. Med. (1980) [Pubmed]
  2. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. DiMarco, J.P., Sellers, T.D., Berne, R.M., West, G.A., Belardinelli, L. Circulation (1983) [Pubmed]
  3. Mechanism of interruption of atrial flutter by moricizine. Electrophysiological and multiplexing studies in the canine sterile pericarditis model of atrial flutter. Ortiz, J., Nozaki, A., Shimizu, A., Khrestian, C., Rudy, Y., Waldo, A.L. Circulation (1994) [Pubmed]
  4. Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil. Tommaso, C., McDonough, T., Parker, M., Talano, J.V. Arch. Intern. Med. (1983) [Pubmed]
  5. Atrial tachyarrhythmias in acute myocardial infarction. Liberthson, R.R., Salisbury, K.W., Hutter, A.M., DeSanctis, R.W. Am. J. Med. (1976) [Pubmed]
  6. Enhanced atrioventricular conduction during atrial flutter after intravenous adenosine. Brodsky, M.A., Allen, B.J., Grimes, J.A., Gold, C. N. Engl. J. Med. (1994) [Pubmed]
  7. Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. Tai, C.T., Chen, S.A., Feng, A.N., Yu, W.C., Chen, Y.J., Chang, M.S. Circulation (1998) [Pubmed]
  8. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Stambler, B.S., Wood, M.A., Ellenbogen, K.A. Circulation (1997) [Pubmed]
  9. Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter. Tai, C.T., Chen, S.A., Chiang, C.E., Lee, S.H., Ueng, K.C., Wen, Z.C., Huang, J.L., Chen, Y.J., Yu, W.C., Feng, A.N., Chiou, C.W., Chang, M.S. Circulation (1997) [Pubmed]
  10. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Stambler, B.S., Wood, M.A., Ellenbogen, K.A., Perry, K.T., Wakefield, L.K., VanderLugt, J.T. Circulation (1996) [Pubmed]
  11. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Feld, G.K., Venkatesh, N., Singh, B.N. Circulation (1986) [Pubmed]
  12. Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. Dias, V.C., Weir, S.J., Ellenbogen, K.A. Circulation (1992) [Pubmed]
  13. Effect of procainamide and N-acetylprocainamide on atrial flutter: studies in vivo and in vitro. Wu, K.M., Hoffman, B.F. Circulation (1987) [Pubmed]
  14. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. Ellenbogen, K.A., Dias, V.C., Plumb, V.J., Heywood, J.T., Mirvis, D.M. J. Am. Coll. Cardiol. (1991) [Pubmed]
  15. Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Foster, R.H., Wilde, M.I., Markham, A. Drugs (1997) [Pubmed]
  16. Risks of intravenous amiodarone in neonates. Gandy, J., Wonko, N., Kantoch, M.J. The Canadian journal of cardiology. (1998) [Pubmed]
  17. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. Guo, G.B., Ellenbogen, K.A., Wood, M.A., Stambler, B.S. J. Am. Coll. Cardiol. (1996) [Pubmed]
  18. Is there a future for antiarrhythmic drug therapy? Guerra, P.G., Talajic, M., Roy, D., Dubuc, M., Thibault, B., Nattel, S. Drugs (1998) [Pubmed]
  19. Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. Derakhchan, K., Pagé, P., Lambert, C., Kus, T. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  20. Further observations on the electrophysiologic effects of oral amiodarone therapy. Santinelli, V., Chiariello, M., Ambrosio, G., Stanislao, M., Condorelli, M. Chest (1982) [Pubmed]
  21. Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death. Rossenbacker, T., Carroll, S.J., Liu, H., Kuipéri, C., de Ravel, T.J., Devriendt, K., Carmeliet, P., Kass, R.S., Heidbüchel, H. Heart rhythm : the official journal of the Heart Rhythm Society. (2004) [Pubmed]
  22. Linear ablation of the isthmus between the inferior vena cava and tricuspid annulus for the treatment of atrial flutter. A study in the canine atrial flutter model. Tabuchi, T., Okumura, K., Matsunaga, T., Tsunoda, R., Jougasaki, M., Yasue, H. Circulation (1995) [Pubmed]
  23. Resolution of cardiomyopathy after ablation of atrial flutter. Luchsinger, J.A., Steinberg, J.S. J. Am. Coll. Cardiol. (1998) [Pubmed]
  24. Left atrial appendage function and thrombus formation in atrial fibrillation-flutter: a transesophageal echocardiographic study. Santiago, D., Warshofsky, M., Li Mandri, G., Di Tullio, M., Coromilas, J., Reiffel, J., Homma, S. J. Am. Coll. Cardiol. (1994) [Pubmed]
  25. Incidence of atrial flutter/fibrillation in adults with atrial septal defect before and after surgery. Berger, F., Vogel, M., Kramer, A., Alexi-Meskishvili, V., Weng, Y., Lange, P.E., Hetzer, R. Ann. Thorac. Surg. (1999) [Pubmed]
  26. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. Hongo, R.H., Themistoclakis, S., Raviele, A., Bonso, A., Rossillo, A., Glatter, K.A., Yang, Y., Scheinman, M.M. J. Am. Coll. Cardiol. (2004) [Pubmed]
  27. Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias. Camm, A.J., Hellestrand, K.J., Nathan, A.W., Bexton, R.S. Drugs (1985) [Pubmed]
  28. Ventricular tachycardia as a complication of atrial flutter ablation. Ramanna, H., Derksen, R., Elvan, A., Simmers, T.A., Wittkampf, F.H., Hauer, R.N., Robles de Medina, E. J. Cardiovasc. Electrophysiol. (2000) [Pubmed]
  29. Dofetilide versus quinidine for atrial flutter: viva la difference!? Olshansky, B. J. Cardiovasc. Electrophysiol. (1996) [Pubmed]
  30. Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Doni, F., Della Bella, P., Kheir, A., Manfredi, M., Piemonti, C., Staffiere, E., Rimondini, A., Fiorentini, C. Am. J. Cardiol. (1995) [Pubmed]
WikiGenes - Universities